We further demonstrated that inhibition of mTOR/PI3K, G2M checkpoint, or the glycolysis pathway through NAMPT inhibition had potent in vitro anti-leukemic activity in human and murine T-ALL cell lines, and inhibitors of G2M checkpoint and NAMPT were effective in human PDX-expanded T-ALL samples of different molecular subtypes. The gene discussed is NAMPT; the disease is acute lymphoblastic leukemia.